Objective: Thymidine kinase 1 (TK1) is a key enzyme in the pyrimidine salvage pathway. Increased TK1 concentration correlates with cell division. TK1 is an emerging biomarker in cancer diagnosis; however, its effectiveness in diagnosis and management for malignant pleural effusion (MPE) is unclear. We evaluated the diagnostic efficiency and prognostic value of pleural effusion TK1 (pTK1) concentration for MPE.
| INTRODUC TI ON
Malignant pleural effusion (MPE) is a common symptom experienced by advanced stage cancer patients. This condition affects 500-700 individuals per million population and accounts for more than 125,000 hospital admissions every year in the United States.
1,2 The estimated median survival for patients with MPE is 3-12 months. 1 However, due to the development of local and systemic therapy, some recent studies have reported increased survival times. 3, 4 Although there has been notable progress in explaining the pathophysiology of MPE, challenges remain in diagnosis and precise prognostic assessment. 5, 6 cal diagnosis, and malignant cells were found in pleural effusion by cytology. The exclusion criteria were patients under 18 years old or with an expected survival of less than 1 month. The patients were followed up for a median of 1 year. Informed consent was obtained from each patient. The ethics research council of our hospital approved the protocol of this study.
| Clinical and biochemical measures
Performance status was assessed using the Eastern Cooperative Oncology Group Performance Status (ECOG PS) score. The pleural effusion samples were collected from the same pleural effusion sample sent for cytology examination. Each sample was stored at 4°C immediately after collection, and then, the TK1 concentration was measured in 24 h using a commercially available chemiluminescence dot blot assay kit (SSTK Biotech, Ltd., Shenzhen, China). Briefly, standards and effusion samples were directly transferred to a nitrocellulose membrane. Then, human anti-TK1 chicken immunoglobulin Y antibody was added to the samples. Next, the light intensities of spots were captured by an imaging system (SSTK Ltd., Shenzhen, China). Finally, curves were created to calculate the concentration.
| Statistical analysis
Normal distributed variables are shown as the mean and standard r-project.org). The nomogram and the optimal cutoff values of continuous variables for survival analysis were determined by using R software with the survminer and rms packages. A P value < 0.05 was considered statistically significant.
| RE SULTS

| Patient characteristics
In total, 210 patients who met the criteria were included in our study. The MPE group included 160 patients. The diseases leading to MPE were lung cancer (143 patients), breast cancer (five patients), esophageal cancer (five patients), gastric cancer (five patients), and mesothelioma (two patients). The BPE group consisted of 50 patients (parapneumonic effusion, 29 patients; tuberculous pleural effusion, 21 patients). Among the 160 patients with MPE, 73 were male and 87 were female, with a mean age of 59.7 ± 9.12.
Regarding 50 patients with BPE, 23 were male and 27 were female, with a mean age of 57.3 ± 9.98.
| Accuracy of pTK1 concentrations to diagnose MPE
The concentration of pTK1 in cases of MPE was 5.01 (3.55-7.63) pmol/L, while in cases of BPE, it was 2.44 (1.81-3.05) pmol/L. The median value of pTK1 in MPE was significantly higher than that in BPE (P < 0.001, Figure 1 . The ROC curve of pTK1 in MPE patients was plotted, and the AUC was 0.881 [95% confidence interval (CI):
0.826-0.937, P < 0.001, Figure 2 ]. PTK1 revealed the highest sensitivity (0.894) and specificity (0.800), with an optimal cutoff value of 3.10 pmol/L.
| PTK1 concentrations and prognosis
Age, gender, smoking, ECOG PS, pathological type, smoking history, multiple metastasis, pTK1, sTK1, T stage, and N stage of primary cancer were regarded as potential cofounders, and Kaplan-Meier 
| Development and validation of the survival model
Multivariate backward stepwise Cox regression analysis was conducted to identify independent factors from statistically significant variables (P < 0.05) proven by Kaplan-Meier univariate analysis 
| D ISCUSS I ON
Although the gold standard of MPE diagnosis is cytopathology, 15 occasionally, several sampling times were required for identification of malignant cancer cells with microscopy. Various markers have been suggested as noninvasive tests to help discriminate between BPE and MPE and to provide prognostic information. 16, 17 The most heavily studied diagnostic biomarker in pleural effusion is carcinoembryonic antigen (CEA). A meta-analysis including 49 studies suggested that the pooled sensitivity and specificity of pleural effusion CEA for diagnosing MPE were 0.549 and 0.962. 14 In a previous study, 18 the diagnostic value of TK, neuron-specific enolase (NSE), CEA, and cytokeratin fragment 19 (CYFRA 21-1) was determined, and the TK concentration was investigated using a radio enzyme assay. The TK concentration had the highest diagnostic accuracy (Youden index:
0.85) among the above markers. In our study, using a cutoff point of 3.10 pmol/L, the sensitivity and specificity of pTK1 for detecting MPE were 0.894 and 0.800, respectively. The LENT score system 19 was calculated by four variables, including pleural fluid lactate dehydrogenase (LDH) level, ECOG PS, neutrophil-to-lymphocyte ratio F I G U R E 4 Nomogram for predicting 1-year overall survival rates in patients with MPE F I G U R E 5 Calibration plot of the nomogram for the probability of 1-year survival (NLR), and tumor type, and it is widely used in risk stratification of MPE patients. However, a recent study suggested that it underestimates the prognosis in patients with MPE caused by lung adenocarcinoma. 20 The recently published PROMISE score system 21 includes a clinical score method and a biological score method, which is a clinical score plus tissue inhibitor of metalloproteinases 1 (TIMP1).
However, this system can only predict the 3-month mortality, and adding TIMP1 to the score system only contributed very modest effects, which limited its clinical value. 22 In our study, pTK1 was proven to be significant in the univariate test, and multivariate Cox regression analysis demonstrated that pTK1 is an independent prognostic factor, contributing to a strong effect in the survival model.
TK exists in two forms: TK1 is found primarily in the cytoplasm, and TK2 is concentrated in mitochondria. 23 Since TK1 is cell-cycle regulated and TK2 is constitutively expressed, the value of sTK1 as a biomarker for diagnosis and its prognostic significance in lung cancer, breast cancer, esophageal cancer, and gastric cancer have been investigated in recent years, [24] [25] [26] and our study analyzed the TK1 concentration in pleural effusion for the first time.
Nomograms have been created to assess survival factors in various malignancies. 27 Nomograms are useful for visualizing prognostic factors and may help physicians make precise and individualized predictions of MPE outcomes. However, to the best of our knowledge, a nomogram to predict the probability of 1-year survival for MPE patients has not been reported.
There are both strengths and limitations in our study. A major limitation of our study was that the sample size was relatively small and performed in a single institution. Another limitation is the lack of external validation for our survival model. Multicenter studies are required to validate the diagnostic and prognostic precision of this model.
| CON CLUS ION
We evaluated the value of measuring pTK1 concentration in the diagnostic and prognostic prediction of MPE and established a nomogram for predicting 1-year survival. As pTK1 measurement is noninvasive and shows high diagnostic and prognostic value, it may be a useful biomarker in MPE management.
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